2020
Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.
Davidoff A, Long J, Huntington S. Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies. Journal Of Clinical Oncology 2020, 38: 38-38. DOI: 10.1200/jco.2020.38.29_suppl.38.Peer-Reviewed Original ResearchLines of therapyCare settingsNon-teaching hospitalsHematologic malignanciesSEER-MedicareContinuous Medicare Parts AMajor cancer sitesMultivariable logistic regressionNew immunomodulatory drugsMultiple myeloma therapyEnd of studyMedicare Part ANCI cancer centersFit patientsCell transplantDiagnosis yearImmunomodulatory drugsTreatment patternsMM diagnosisCancer CenterPatient populationCancer sitesMyeloma therapyAcademic hospitalLower odds
2019
Healthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML
2015
A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
Svoboda J, Strelec L, Shah N, Chong E, Montrey K, Walsh K, Huntington S, Mato A, Landsburg D, Nasta S, Schuster S. A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas. Journal Of Clinical Oncology 2015, 33: 8553-8553. DOI: 10.1200/jco.2015.33.15_suppl.8553.Peer-Reviewed Original Research